# Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

> **NCT06238336** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shanxi Bethune Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hematological Malignancy

## Interventions

- **DRUG:** CAR-T cell therapy

## Key facts

- **NCT ID:** NCT06238336
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-15
- **Primary completion:** 2025-11-15
- **Final completion:** 2025-12-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238336, "Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06238336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*